Abstract:【Abstract】 Objective To make a detailed survey of the status for βblockers using on chronic heart failure (CHF) during hospitalization in the Department of Cardiology, The Affiliated Hospital of North Sichuan Medical College. Methods A retrospective investigation was conducted on the use of βblockers in patients with chronic heart failure in 2017 by using the database of inpatients in the Affiliated Hospital of North Sichuan Medical College. Results 486 patients with CHF were hospitalized in 2017 in the Department of Cardiology, Affiliated Hospital of North Sichuan Medical College, mainly due to ischemic heart disease. Among them, 309 patients (63.58%) used β-blockers. They all used secondgeneration βblockers, including metoprolol and bisoprolol, with an average dose of 3165 mg/d and 333 mg/d. Metoprolol (247 cases, 79.94% ) was the most commonly used. There was a significant statistical difference in gender, age, and New York Heart Association (NYHA) functional class (P<0.05). There was no statistical difference between the two groups in terms of ejection fraction and heart rate (P>0.05). βblockers can reduce heart rate, systolic blood pressure and diastolic blood pressure in patients with CHF, there was a significant statistical difference between them(P<0.001). Its controlling rate of heart rate was only 2.91%. Conclusion In 2017, the main cause of chronic heart failure in the Affiliated Hospital of North Sichuan Medical College was ischemic heart disease. Second generation beta blockers were used in all patients with chronic heart failure, metoprolol was the most commonly used. Sex, age and NYHA classification may be the factors that affect the use of β - blockers in patients with chronic heart failure in the Affiliated Hospital of North Sichuan Medical College. The heart rate and blood pressure of patients with chronic heart failure after using β - blocker were lower than before, but the rate of heart rate reaching standard was very low at discharge.